Class IIDrug
Dopamine HCl Inj. recall
Summary
Pfizer is recalling Dopamine HCl Inj. (drug). According to the FDA report, the reason is: Lack of Assurance of Sterility. The FDA rated this a Class II: the product may cause temporary or medically reversible health problems; serious harm is unlikely. Recall status: Ongoing.
Details from the FDA report
- Product
- Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
- Reason
- Lack of Assurance of Sterility
- Lot / code info
- Lot # NL5230, Exp Date:10/2027
- Quantity
- N/A
- Distribution
- US Nationwide.
- Recalling company
- Pfizer, Manhattan, NY United States
- Recall started
- September 4, 2026
- FDA report date
- September 23, 2026
- Classification
- Class II: The product may cause temporary or medically reversible health problems; serious harm is unlikely.
- Voluntary / mandated
- Voluntary: Firm initiated
- Status
- Ongoing
- Recall number
- D-0853-2026
What to do
- Check whether you have this product, and compare the lot numbers, codes, or dates on your package with the codes listed above.
- If it matches, stop using it and keep it away from children and pets.
- Contact the recalling company (Pfizer) or the store where you bought it about returns or refunds.
- Do not stop a prescribed medication without first talking to your pharmacist or doctor; they can help find a safe replacement.
- If you think the product made you or someone else sick, contact a doctor or pharmacist. In an emergency call 911.
- You can report problems to the FDA via MedWatch.